OBJECTIVES: Spinal cord stimulation (SCS) has been shown to be an effective and safe option to treat patients with intractable pain in the general population. Our study examined the experience of US veterans with SCS. METHODS: We reviewed electronic health records and conducted phone interviews with 65 veterans who had SCS from 2008 to 2020 at the Southeastern Louisiana Veterans Health Care System (SLVHCS). Our primary outcome measure was veteran would recommend SCS to peers. Secondary outcomes were improvements in activities of daily living and ability to decrease opioid pain medications. RESULTS: A majority (77%) of veterans recommended SCS to their peers. Statistical difference was seen in 16 of 18 categories of activities of daily living based on the Pain Outcomes Questionnaire. No permanent neurologic deficits or deaths were associated with SCS use. There were no neurological sequelae. Three patients (5%) developed skin dehiscence postimplant and were treated with explant surgery but all were eager to get a new SCS implanted. CONCLUSION: Veterans at SLVHCS were satisfied with their experience using SCS and few experienced adverse effects.
OBJECTIVES: Spinal cord stimulation (SCS) has been shown to be an effective and safe option to treat patients with intractable pain in the general population. Our study examined the experience of US veterans with SCS. METHODS: We reviewed electronic health records and conducted phone interviews with 65 veterans who had SCS from 2008 to 2020 at the Southeastern Louisiana Veterans Health Care System (SLVHCS). Our primary outcome measure was veteran would recommend SCS to peers. Secondary outcomes were improvements in activities of daily living and ability to decrease opioid pain medications. RESULTS: A majority (77%) of veterans recommended SCS to their peers. Statistical difference was seen in 16 of 18 categories of activities of daily living based on the Pain Outcomes Questionnaire. No permanent neurologic deficits or deaths were associated with SCS use. There were no neurological sequelae. Three patients (5%) developed skin dehiscence postimplant and were treated with explant surgery but all were eager to get a new SCS implanted. CONCLUSION: Veterans at SLVHCS were satisfied with their experience using SCS and few experienced adverse effects.
Authors: Damian G Hoy; Emma Smith; Marita Cross; Lidia Sanchez-Riera; Rachelle Buchbinder; Fiona M Blyth; Peter Brooks; Anthony D Woolf; Richard H Osborne; Marlene Fransen; Tim Driscoll; Theo Vos; Jed D Blore; Chris Murray; Nicole Johns; Mohsen Naghavi; Emily Carnahan; Lyn M March Journal: Ann Rheum Dis Date: 2014-02-18 Impact factor: 19.103
Authors: Krishna Kumar; Rod S Taylor; Line Jacques; Sam Eldabe; Mario Meglio; Joan Molet; Simon Thomson; Jim O'Callaghan; Elon Eisenberg; Germain Milbouw; Eric Buchser; Gianpaolo Fortini; Jonathan Richardson; Richard B North Journal: Pain Date: 2007-09-12 Impact factor: 6.961
Authors: Elias Veizi; Salim M Hayek; James North; T Brent Chafin; Thomas L Yearwood; Louis Raso; Robert Frey; Kevin Cairns; Anthony Berg; John Brendel; Nameer Haider; Matthew McCarty; Henry Vucetic; Alden Sherman; Lilly Chen; Nitzan Mekel-Bobrov Journal: Pain Med Date: 2017-08-01 Impact factor: 3.750
Authors: Jason E Pope; Timothy R Deer; Steven Falowski; David Provenzano; Michael Hanes; Salim M Hayek; Jacob Amrani; Jonathan Carlson; Ioannis Skaribas; Kris Parchuri; W Porter McRoberts; Robert Bolash; Nameer Haider; Maged Hamza; Kasra Amirdelfan; Sean Graham; Corey Hunter; Eric Lee; Sean Li; Michael Yang; Lucas Campos; Shrif Costandi; Robert Levy; Nagy Mekhail Journal: Neuromodulation Date: 2017-07-17
Authors: Jean-Pierre Van Buyten; Frank Wille; Iris Smet; Carin Wensing; Jennifer Breel; Edward Karst; Marieke Devos; Katja Pöggel-Krämer; Jan Vesper Journal: Neuromodulation Date: 2017-08-18